Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer

International Journal of Cancer

Volumn 130, Issue 5, 2012, Pages 1021-1028

  Obinata, Daisuke ^a,b   Takayama, Ken Ichi ^a,c   Urano, Tomohiko ^a,c   Murata, Taro ^a   Kumagai, Jinpei ^a   Fujimura, Tetsuya ^a   Ikeda, Kazuhiro ^c   Horie Inoue, Kuniko ^c   Homma, Yukio ^a   Ouchi, Yasuyoshi ^a   Takahashi, Satoru ^b   Inoue, Satoshi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

androgen receptor; Oct1; prognostic factor; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 1; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE SILENCING; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; SURVIVAL RATE;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; NEOPLASM GRADING; OCTAMER TRANSCRIPTION FACTOR-1; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA INTERFERENCE;

EID: 84155165637     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26043     Document Type: Article

References (28)

1. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308. (Pubitemid 38501396)
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM,. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9.
3. Heinlein CA, Chang C,. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002; 23: 175-200. (Pubitemid 34299023)
4. Prefontaine GG, Lemieux ME, Giffin W, Schild-Poulter C, Pope L, LaCasse E, Walker P, Hache RJ,. Recruitment of octamer transcription factors to DNA by glucocorticoid receptor. Mol Cell Biol 1998; 18: 3416-30. (Pubitemid 28240514)
5. Kutoh E, Stromstedt PE, Poellinger L,. Functional interference between the ubiquitous and constitutive octamer transcription factor 1 (OTF-1) and the glucocorticoid receptor by direct protein-protein interaction involving the homeo subdomain of OTF-1. Mol Cell Biol 1992; 12: 4960-9.
6. Verrijzer CP, Van der Vliet PC,. POU domain transcription factors. Biochim Biophys Acta 1993; 1173: 1-21. (Pubitemid 23125489)
7. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M,. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380-92. (Pubitemid 47126935)
8. He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q, Zhang Y, Xu K, Ni M, Lupien M, Mieczkowski P, Lieb JD, et al. Nucleosome dynamics define transcriptional enhancers. Nat Genet 2010; 42: 343-7.
9. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G,. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28: 928-34. (Pubitemid 38856850)
10. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, Ijichi N, Ouchi Y, Shirahige K, Aburatani H, Inoue S,. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 2007; 26: 4453-63. (Pubitemid 47014467)
11. Kumagai J, Urano T, Ogushi T, Takahashi S, Horie-Inoue K, Fujimura T, Azuma K, Muramatsu M, Ouchi Y, Kitamura T, Inoue S,. EBAG9 is a tumor-promoting and prognostic factor for bladder cancer. Int J Cancer 2009; 124: 799-805.
12. Saez AI, Artiga MJ, Sanchez-Beato M, Sanchez-Verde L, Garcia JF, Camacho FI, Franco R, Piris MA,. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas. Mod Pathol 2002; 15: 211-20. (Pubitemid 34246618)
13. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL,. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-6. (Pubitemid 23046895)
14. Lu S, Tsai SY, Tsai MJ,. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997; 57: 4511-6. (Pubitemid 27441054)
15. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, Chen T, Buchanan G, Frenkel B, Coetzee GA,. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 2008; 3: e3645.
16. Jariwala U, Cogan JP, Jia L, Frenkel B, Coetzee GA,. Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions. Prostate 2009; 69: 392-400.
17. Ewen ME,. Where the cell cycle and histones meet. Genes Dev 2000; 14: 2265-70.
18. Schild-Poulter C, Shih A, Yarymowich NC, Hache RJ,. Down-regulation of histone H2B by DNA-dependent protein kinase in response to DNA damage through modulation of octamer transcription factor 1. Cancer Res 2003; 63: 7197-205. (Pubitemid 37413458)
19. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM,. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9. (Pubitemid 32685750)
20. Agoulnik IU, Vaid A, Bingman WE, 3rd, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL,. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005; 65: 7959-67. (Pubitemid 41297275)
21. Marcelli M, Cunningham GR,. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999; 84: 3463-8. (Pubitemid 30645192)
22. Culig Z, Klocker H, Bartsch G, Hobisch A,. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002; 9: 155-70. (Pubitemid 35175976)
23. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9. (Pubitemid 38524696)
24. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45. (Pubitemid 33741879)
25. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71.
26. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46.
27. Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, et al. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 2009; 1: 62-71.
28. Rosenblatt AE, Burnstein KL,. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Mol Endocrinol 2009; 23: 412-21.